Recurrent Melanoma Completed Phase 2 Trials for Sargramostim (DB00020)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00019890Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic MelanomaTreatment